newsfilter
← Latest News
GlobeNewswire·

ObsEva Announces Progress on Restructuring Initiatives

$7.6 million annual savings expected via reduction-in-force currently underway $6.2 million savings expected from assignment of legacy linzagolix program contracts to Kissei Pharmaceutical Co., Ltd., including $1.7 million of accounts payable assigned